Role of Apathy in the Effectiveness of Weight Loss Interventions

Not Applicable

Completed

• Conditions: Obesity; Apathy
• Interventions: Behavioral: medical crisis councelling; Drug: methyphenidate; Behavioral: MOVE

• Registration Number: NCT00548652
• Lead Sponsor: VA Nebraska Western Iowa Health Care System

Brief Summary

The purpose of this study is to determine whether treating apathy with methylphenidate or medical Crisis counselling will increase adherence to weight loss programs thereby increasing their effectiveness

Detailed Description

Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients

Objective: Obesity is a major public health problem. Apathy is a common behavioral problem characterized by loss of initiative, poor motivation and persistence. Presence of apathy impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's ability to seek new interactions, life styles and new treatment options for obesity. Lack of motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack of persistence impairs the compliance with these regimens. Thus, apathy influences all stages of self-care. We hypothesize that the treatment of apathy will result in better adherence to weight loss interventions in obese veterans enrolled in the MOVE program.

Research Design: A prospective open label randomized study. Group 1 will have patients with obesity as defined as BMI\>30, and apathy defined as AES score of \> 40. This group will be treated with standard nutrition counseling. Group 2 will have patients with obesity and apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program is a national VA weight loss program). Group 3 will be treated with methylphenidate along with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and the medical crisis counseling along with the MOVE enhancement program.

Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All patients will be in the study for duration of six months. All patients in the methylphenidate arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every week for nine sessions and then every other week till the end of the study

Clinical Relationships/Significance: The prevalence of obesity in the general population is over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since obesity predisposes to several co-morbid conditions such as hypertension, diabetes and cardiovascular disease, it is important to develop interventions that are effective in inducing weight loss. Since apathy plays a large role in the self care behaviours that lead to obesity, treating apathy may improve adherence to weight loss programs

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2007-10-23
• Study First Submitted QC: 2007-10-23
• Study First Posted: 2007-10-24
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Results First Submitted: 2018-06-19
• Status Verified: 2019-10
• Results First Submitted QC: 2019-10-02
• Last Update Submitted: 2019-10-02
• Results First Posted: 2019-10-04
• Last Update Posted: 2019-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 101

Inclusion Criteria

• BMI >30
• Apathy score >40

Exclusion Criteria

• History of cancer, except basal cell
• Cardiovascular event in last 6 months
• Renal failure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
5	MOVE	MOVE plus methyphenidate plus medical crisis counselling
4	MOVE	MOVE plus methylphenidate
2	MOVE	MOVE -weight loss intervention
3	medical crisis councelling	MOVE plus medical crisis counselling
3	MOVE	MOVE plus medical crisis counselling
5	methyphenidate	MOVE plus methyphenidate plus medical crisis counselling
4	methyphenidate	MOVE plus methylphenidate
5	medical crisis councelling	MOVE plus methyphenidate plus medical crisis counselling

Primary Outcome Measures

Name	Time	Method
Apathy Evaluation Scale	6 months	Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score

Secondary Outcome Measures

Name	Time	Method
Change in Weight	6 months	value at 6 months minus value at baseline

Trial Locations

Locations (1)

VA Medical Center, Omaha; 🇺🇸 Omaha, Nebraska, United States